nach oben

Erschienen in:

31.05.2022 | Preclinical study

Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer

verfasst von: Masanori Oshi, Shipra Gandhi, Li Yan, Yoshihisa Tokumaru, Rongrong Wu, Akimitsu Yamada, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Reactive oxygen species (ROS) are oxygen-containing molecules that have high reactivity and play roles in protection or harm the cancer cells. We aimed to clarify the clinical relevance of ROS in breast cancer (BC) tumor microenvironment (TME). We hypothesized that it is associated with worse BC patient outcomes.

Methods

ROS score was generated by Gene Set Variation Analysis of Hallmark ROS pathway gene set and a total of 6245 BC patients were analyzed.

Results

High ROS BC significantly enriched cell proliferation-related gene sets (MYC targets v1 and v2, G2M checkpoint, E2F targets), pro-cancer-related gene sets (DNA repair, unfolded protein response, MTORC1 signaling, PI3K/AKT/MTOR signaling, glycolysis, and oxidative phosphorylation), immune-related gene sets (inflammatory response, allograft rejection, interferon-α and γ responses, complement, and IL6/JAK/STAT3 signaling), and infiltrated immune cells (CD4⁺ memory and CD8⁺ T cells, Th1 and Th2, dendritic cells, Tregs, M1 and M2 macrophages) and B cells, as well as elevated cytolytic activity consistently in both METABRIC and GSE96058 cohorts. Cancer cells were the major source of ROS in BC TME of single-cell sequence (GSE75688) cohort. High ROS was associated with intratumor heterogeneity, homologous recombination defects, mutation rates, and neoantigens, and with clinical aggressiveness in AJCC stage, Nottingham grade and Ki67 expression, as well as worse overall survival in both GSE96058 and METABRIC, and with worse disease-specific survival in METABRIC.

Conclusion

Abundant ROS in BC patients is associated with abundant mutations, aggressive cancer biology, immune response, and worse survival.

Nur mit Berechtigung zugänglich

Zhou Z, Ni K, Deng H, Chen X (2020) Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Adv Drug Deliv Rev 158:73–90PubMedCrossRef

Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24:R453-462PubMedPubMedCentralCrossRef

Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749–762PubMedPubMedCentralCrossRef

Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24:981–990PubMedPubMedCentralCrossRef

Jenkins T, Gouge J (2021) Nrf2 in cancer detoxifying enzymes and cell death programs. Antioxidants 10:1030PubMedPubMedCentralCrossRef

Kimmelman AC (2011) The dynamic nature of autophagy in cancer. Genes Dev 25:1999–2010PubMedPubMedCentralCrossRef

Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, Shumaker DK, Kosak ST, Chandel NS, Goldman RD (2011) The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 25:2579–2593PubMedPubMedCentralCrossRef

Martinon F (2010) Signaling by ROS drives inflammasome activation. Eur J Immunol 40:616–619PubMedCrossRef

Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210–215PubMedCrossRef

10.

Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef

11.

Malla R, Surepalli N, Farran B, Malhotra SV, Nagaraju GP (2021) Reactive oxygen species (ROS): critical roles in breast tumor microenvironment. Crit Rev Oncol Hematol 160:103285PubMedCrossRef

12.

Kalyanaraman B, Cheng G, Hardy M, Ouari O, Bennett B, Zielonka J (2018) Teaching the basics of reactive oxygen species and their relevance to cancer biology: mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies. Redox Biol 15:347–362PubMedCrossRef

13.

Sajadimajd S, Yazdanparast R (2015) Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements. Mol Cell Biochem 408:89–102PubMedCrossRef

14.

Takahashi H, Asaoka M, Yan L, Rashid OM, Oshi M, Ishikawa T, Nagahashi M, Takabe K (2020) Biologically aggressive phenotype and anti-cancer immunity counterbalance in breast cancer with high mutation rate. Sci Rep 10:1852PubMedPubMedCentralCrossRef

15.

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1:417–425PubMedPubMedCentralCrossRef

16.

Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K (2020) High G2M pathway score pancreatic cancer is associated with worse survival, particularly after margin-positive (R1 or R2) resection. Cancers 12:2871PubMedCentralCrossRef

17.

Oshi M, Patel A, Le L, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K (2021) G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Am J Cancer Res 11:3070–3084PubMedPubMedCentral

18.

Oshi M, Satyananda V, Angarita FA, Kim TH, Tokumaru Y, Yan L, Matsuyama R, Endo I, Nagahashi M, Takabe K (2021) Angiogenesis is associated with an attenuated tumor microenvironment, aggressive biology, and worse survival in gastric cancer patients. Am J Cancer Res 11:1659–1671PubMedPubMedCentral

19.

Oshi M, Kim TH, Tokumaru Y, Yan L, Matsuyama R, Endo I, Cherkassky L, Takabe K (2021) Enhanced DNA repair pathway is associated with cell proliferation and worse survival in Hepatocellular Carcinoma (HCC). Cancers 13:323PubMedPubMedCentralCrossRef

20.

Patel A, Oshi M, Yan L, Matsuyama R, Endo I, Takabe K (2021) The unfolded protein response is associated with cancer proliferation and worse survival in hepatocellular carcinoma. Cancers 13:4443PubMedPubMedCentralCrossRef

21.

Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I, Takabe K (2020) Degree of early estrogen response predict survival after endocrine therapy in primary and metastatic ER-positive breast cancer. Cancers 12:3557PubMedCentralCrossRef

22.

Tokumaru Y, Oshi M, Katsuta E, Yan L, Satyananda V, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K (2020) KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. Am J Cancer Res 10:897–907PubMedPubMedCentral

23.

Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Nagahashi M, Takabe K (2020) Intra-tumoral angiogenesis is associated with inflammation immune reaction and metastatic recurrence in breast cancer. Int J Mol Sci 21:6708PubMedCentralCrossRef

24.

Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K (2020) Inflammation is associated with worse outcome in the whole cohort but with better outcome in triple-negative subtype of breast cancer patients. J Immunol Res 2020:5618786PubMedPubMedCentralCrossRef

25.

Gandhi S, Oshi M, Murthy V, Repasky EA, Takabe K (2021) Enhanced thermogenesis in triple-negative breast cancer is associated with pro-tumor immune microenvironment. Cancers 13:2559PubMedPubMedCentralCrossRef

26.

Oshi M, Tokumaru Y, Angarita FA, Lee L, Yan L, Matsuyama R, Endo I, Takabe K (2021) Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Sci Rep 11:12541PubMedPubMedCentralCrossRef

27.

Murthy V, Oshi M, Tokumaru Y, Endo I, Takabe K (2021) Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer. Am J Cancer Res 11:3674–3687PubMedPubMedCentral

28.

Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R, Endo I, Takabe K (2020) G2M cell cycle pathway score as a prognostic biomarker of metastasis in estrogen receptor (ER)-positive breast cancer. Int J Mol Sci 21:2921PubMedCentralCrossRef

29.

Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, Endo I, Takabe K (2020) The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+/HER2- breast cancer. Cells 9:1643PubMedCentralCrossRef

30.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C (2019) Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567:399–404PubMedPubMedCentralCrossRef

31.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352PubMedPubMedCentralCrossRef

32.

Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Häkkinen J, George AM, Chen Y, Ehinger A, Larsson C, Loman N, Malmberg M, Rydén L, Borg Å, Saal LH (2020) The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. EMBO Mol Med 12:e12118PubMedPubMedCentralCrossRef

33.

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173:400-416.e411PubMedPubMedCentralCrossRef

34.

Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park YH, Kan Z, Han W, Park WY (2017) Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun 8:15081PubMedPubMedCentralCrossRef

35.

Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7PubMedPubMedCentralCrossRef

36.

Narayanan S, Kawaguchi T, Yan L, Peng X, Qi Q, Takabe K (2018) Cytolytic activity score to assess anticancer immunity in colorectal cancer. Ann Surg Oncol 25:2323–2331PubMedPubMedCentralCrossRef

37.

Takeshita T, Torigoe T, Yan L, Huang JL, Yamashita H, Takabe K (2020) The impact of immunofunctional phenotyping on the malfunction of the cancer immunity cycle in breast cancer. Cancers 13:110PubMedCentralCrossRef

38.

Oshi M, Kawaguchi T, Yan L, Peng X, Qi Q, Tian W, Schulze A, McDonald KA, Narayanan S, Young J, Liu S, Morris LG, Chan TA, Kalinski P, Matsuyama R, Otsuji E, Endo I, Takabe K (2021) Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. Am J Cancer Res 11:3628–3644PubMedPubMedCentral

39.

Oshi M, Gandhi S, Huyser MR, Tokumaru Y, Yan L, Yamada A, Matsuyama R, Endo I, Takabe K (2021) MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy. Am J Cancer Res 11:4421–4437PubMedPubMedCentral

40.

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61PubMedPubMedCentralCrossRef

41.

Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:220PubMedPubMedCentralCrossRef

42.

Oshi M, Asaoka M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Zsiros E, Ishikawa T, Endo I, Takabe K (2020) Abundance of regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer. Cancers 12:3038PubMedCentralCrossRef

43.

Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K (2020) ITPKC as a prognostic and predictive biomarker of neoadjuvant chemotherapy for triple negative breast cancer. Cancers 12:2758PubMedCentralCrossRef

44.

Oshi M, Tokumaru Y, Patel A, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K (2020) A novel four-gene score to predict pathologically complete (R0) resection and survival in pancreatic cancer. Cancers 12:3635PubMedCentralCrossRef

45.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA et al (2019) The immune landscape of cancer. Immunity 51:411–412PubMedCrossRef

46.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550PubMedPubMedCentralCrossRef

47.

Satyananda V, Oshi M, Tokumaru Y, Maiti A, Hait N, Matsuyama R, Endo I, Takabe K (2021) Sphingosine 1-phosphate (S1P) produced by sphingosine kinase 1 (SphK1) and exported via ABCC1 is related to hepatocellular carcinoma (HCC) progression. Am J Cancer Res 11:4394–4407PubMedPubMedCentral

48.

Katsuta E, Huyser M, Yan L, Takabe K (2021) A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma. Am J Cancer Res 11:4294–4307PubMedPubMedCentral

49.

Oshi M, Gandhi S, Angarita FA, Kim TH, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K (2021) A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. Am J Cancer Res 11:3611–3627PubMedPubMedCentral

50.

Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Kalinski P, Endo I, Takabe K (2020) Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (cDC). Cancers 12:3342PubMedCentralCrossRef

51.

Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K (2020) CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci 21:6968PubMedCentralCrossRef

52.

Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1–40PubMedCrossRef

53.

Harman D (2006) Free radical theory of aging: an update: increasing the functional life span. Ann NY Acad Sci 1067:10–21PubMedCrossRef

54.

Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr (2002) Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 158:220–235PubMedCrossRef

55.

Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86:477–486PubMedCrossRef

56.

Higinbotham KG, Rice JM, Diwan BA, Kasprzak KS, Reed CD, Perantoni AO (1992) GGT to GTT transversions in codon 12 of the K-ras oncogene in rat renal sarcomas induced with nickel subsulfide or nickel subsulfide/iron are consistent with oxidative damage to DNA. Can Res 52:4747–4751

57.

Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Pontén J (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124–10128PubMedPubMedCentralCrossRef

58.

Poulsen HE, Prieme H, Loft S (1998) Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 7:9–16PubMed

59.

Weinberg SE, Sena LA, Chandel NS (2015) Mitochondria in the regulation of innate and adaptive immunity. Immunity 42:406–417PubMedPubMedCentralCrossRef

60.

Kirtonia A, Sethi G, Garg M (2020) The multifaceted role of reactive oxygen species in tumorigenesis. Cell Mol Life Sci 77:4459–4483PubMedCrossRef

61.

Mougiakakos D, Johansson CC, Kiessling R (2009) Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113:3542–3545PubMedCrossRef

62.

Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG (2013) ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res 23:898–914PubMedPubMedCentralCrossRef

63.

Giovanelli P, Sandoval TA, Cubillos-Ruiz JR (2019) Dendritic cell metabolism and function in tumors. Trends Immunol 40:699–718PubMedCrossRef

64.

Chougnet CA, Thacker RI, Shehata HM, Hennies CM, Lehn MA, Lages CS, Janssen EM (2015) Loss of phagocytic and antigen cross-presenting capacity in aging dendritic cells is associated with mitochondrial dysfunction. J Immunol 195:2624–2632PubMedCrossRef

65.

Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, Hashimoto A, Kapralov A, Amoscato A, Angelini R, Patel S, Alicea-Torres K, Weiner D, Murphy ME, Klein-Seetharaman J, Celis E, Kagan VE, Gabrilovich DI (2017) Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun 8:2122PubMedPubMedCentralCrossRef

66.

Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M (2020) Reactive oxygen species and antitumor immunity-from surveillance to evasion. Cancers 12:1748PubMedCentralCrossRef

67.

Guo S, Burcus NI, Scott M, Jing Y, Semenov I (2021) The role of reactive oxygen species in the immunity induced by nano-pulse stimulation. Sci Rep 11:23745PubMedPubMedCentralCrossRef

68.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550PubMedCrossRef

69.

Wang Q, Xiang Q, Yu L, Hu T, Chen Y, Wang J, Nie X, Cheng J (2019) Changes in tumor-infiltrating lymphocytes and vascular normalization in breast cancer patients after neoadjuvant chemotherapy and their correlations with DFS. Front Oncol 9:1545PubMedCrossRef

70.

Nagahashi M, Hait NC, Maceyka M, Avni D, Takabe K, Milstien S, Spiegel S (2014) Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv Biol Regul 54:112–120PubMedCrossRef

Titel: Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer
verfasst von: Masanori Oshi
Shipra Gandhi
Li Yan
Yoshihisa Tokumaru
Rongrong Wu
Akimitsu Yamada
Ryusei Matsuyama
Itaru Endo
Kazuaki Takabe
Publikationsdatum: 31.05.2022
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-022-06633-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer